LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND
2 E- s, N9 A/ b% `4 p0 DTHERAPE UTIC PERSPECTIVES# y: Z' d2 H ^8 a! p; q) p
J. Mazieres, S. Peters8 m( r" @; x5 F" ?8 K
Introduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
2 \! P; V( a M7 eoutcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted) A/ N6 X1 C/ u0 B5 p
treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2
7 P# G4 B" c+ E1 ]treatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
; J- ^7 W9 ^9 G. Z! |and 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;
. K9 P& N# R, ~* sdisease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for a1 G" p9 V7 v1 Z4 |
trastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to
$ m W' I6 }* t2 @* C' k: o2 d mlapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and. N, S# Q" _ s2 o/ V# g
22.9 months for respectively early stage and stag e IV patients.
$ H- E/ \6 N( b: EConclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,. @0 p* Q$ ]! j1 U/ P4 T
reinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .; W8 m9 w4 }$ @% t' {1 |
HER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative
2 |; f) ~1 Z& ]# @clinicaltrials.8 S t1 X% n7 q( `7 G: W. ]4 I1 r
|